The CMS rebate is only for the LDT version of the test, there is no way they are going to achieve any decent sales via this pathway.
The test needs FDA approval, which they were trying to achieve in 2021 and then went silent? why? hmmm... not a single mention of their FDA submission after the pre-submission package. Why?
Why did the Australia MSAC reject the application?
Why has EVERY country they have tried to enter fail?
You have to look at the facts and data here, not what Richard is saying. There is a BIG disconnect between what Richard says and what is actually achieved.
Even the endo test raises several questions which I won't discuss any further right now.
I was a long term believer in PIQ and was lucky to sell with profit, but as the red flags started showing up I got out and thank god I did.
The CMS rebate is only for the LDT version of the test, there is...
Add to My Watchlist
What is My Watchlist?
